| Outcome Measures: |
Primary: Percentage of time with glucose values < 3.9 mmol/l as measured by the continuous glucose monitor, Percentage, 26 hours during closed-loop control | Secondary: Number of carbohydrate interventions to treat hypoglycemia, 26 hours during closed-loop control|Percentage of time with glucose values in the range 3.9-10.0 mmol/l measured by continuous glucose monitor and plasma glucose, Percentage, 26 hours during closed-loop control|Percentage of time with glucose values < 3.9 mmol/l as measured by plasma glucose, Percentage, 26 hours during closed-loop control|Percentage of time with glucose values in the range > 13.9 mmol/l measured by continuous glucose monitor and plasma glucose, Percentage, 26 hours during closed-loop control|Percentage of time with glucose values < 3.0 mmol/l as measured by continuous glucose monitor and plasma glucose, Percentage, 26 hours during closed-loop control|Mean blood glucose value measured by continuous glucose monitor and plasma glucose, mmol/L, 26 hours during closed-loop control|Number of hypoglycemic episodes < 3.9 mmol/l on continuous glucose monitor and plasma glucose, No., 26 hours during closed-loop control|Continuous glucose monitored glycemic variability measured as SD, mmol/L, 26 hours during closed-loop control|Continuous glucose monitored glycemic variability measured as CV, percentage, 26 hours during closed-loop control|Composite outcome: Percentage of participants achieving (1) time in range (3.9-10) > 70 %, (2) time in alert hypoglycemia (<3.9 mmol/l) < 4 %, and (3) time in clinical hypoglycemia (<3.0 mmol) < 1% as measured by CGM and YSI, percentage, 26 hours during closed-loop control|Total insulin dose, units, 26 hours during closed-loop control|Total glucagon dose, mg, 26 hours during closed-loop control|Number of manual insulin boluses, No., 26 hours during closed-loop control|Number of adverse events - Nausea, No of event if visual analog scale (0-100) increase \>10 from baseline, 26 hours during closed-loop control|Number of adverse events - Headache, No of event if visual analog scale (0-100) increase \>10 from baseline, 26 hours during closed-loop control|Number of adverse events - Palpitation, No of event if visual analog scale (0-100) increase \>10 from baseline, 26 hours during closed-loop control|Number of vomits, No of event if visual analog scale (0-100) increase \>10 from baseline, 26 hours during closed-loop control|Difference between actual and participant-estimated carbohydrate content in meals, g per meal, 26 hours of closed-loop glucose control|Mean Borg scale, Scale of perceived exertion from 6 (no effort activity) to 20 (max effort activity), During 45 minutes exercise|Physical activity intensity measured by ActiGraph GT9X Link, Percentage of sedentary activity, 26 hours|Sleep efficiency measured by ActiGraph GT9X Link, The ratio of total sleep time to time in bed, 26 hours
|
